SUTRO BIOPHARMA, INC. (STRO) Operating Income (Loss) USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Sutro Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2024.
  • Sutro Biopharma, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$56.6 M, a 34% decline year-over-year.
  • Sutro Biopharma, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$104 M, a 21.5% increase year-over-year.
  • Sutro Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$89.3 M, a 30.8% increase from 2022.
  • Sutro Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$129 M, a 30.9% decline from 2021.
  • Sutro Biopharma, Inc. annual Operating Income (Loss) for 2021 was -$98.5 M, a 38.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$104 M -$56.6 M -$14.4 M -34% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$89.3 M $43.2 M +$92.4 M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$182 M -$44 M -$22.8 M -108% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$159 M -$46.2 M -$26.8 M -138% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$132 M -$42.2 M -$3.11 M -7.94% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$129 M -$49.2 M -$14.2 M -40.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$115 M -$21.2 M +$13.5 M +38.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$128 M -$19.4 M -$9.57 M -97.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$119 M -$39.1 M -$20.1 M -106% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$98.5 M -$35 M -$10.2 M -41% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-25
Q3 2021 -$88.3 M -$34.7 M -$24.1 M -227% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$64.3 M -$9.81 M +$6.61 M +40.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$70.9 M -$19 M +$171 K +0.89% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$71.1 M -$24.8 M -$10.1 M -68.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-30
Q3 2020 -$61 M -$10.6 M +$2.12 M +16.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$63.1 M -$16.4 M -$2.73 M -20% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$60.4 M -$19.2 M -$4.91 M -34.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 -$55.5 M -$14.8 M -$11.5 M -351% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 -$44 M -$12.7 M -$2.58 M -25.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$41.4 M -$13.7 M -$1.6 M -13.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$39.8 M -$14.3 M -$2.56 M -21.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$37.2 M -$3.28 M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-18
Q3 2018 -$10.2 M -$9.09 M -854% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$12.1 M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$11.7 M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q3 2017 -$1.07 M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.